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Abstract
Systematic reviews can often reveal much more than the original objective of the work. The objectives of this retrospective
analysis were to answer three basic questions about blood pressure variability: 1) Does blood pressure entry criterion have
an effect on baseline blood pressure variability? 2) Do thiazide diuretics have a significant effect on blood pressure
variability? and 3) Does systolic blood pressure vary to the same degree as diastolic blood pressure? This analysis of blood
pressure variability is based on resting standardized research setting BP readings from two systematic reviews evaluating
blood pressure lowering efficacy of thiazide diuretics from double blind randomized controlled trials in 33,611 patients with
primary hypertension. The standard deviation reported in trials was the focus of the research and the unit of analysis. When
a threshold systolic or diastolic blood pressure value is used to determine entry into a trial, baseline variability is significantly
decreased, systolic from 14.0 to 9.3 mmHg and diastolic from 8.4 to 5.3 mmHg. Thiazides do not change BP variability as the
standard deviation and coefficient of variation of systolic blood pressure and diastolic blood pressure did not differ between
thiazide and placebo groups at end of treatment. The coefficient of variation of systolic blood pressure was significantly
greater than the coefficient of variation of diastolic blood pressure. Entry criterion decreases the baseline blood pressure
variability. Treatment with a thiazide diuretic does not affect blood pressure variability. Systolic blood pressure varies to a
greater degree than diastolic blood pressure.
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Introduction
Blood pressure (BP) measurements are highly variable. This is a
fact that is commonly not appreciated and variability of blood
pressure in an individual could be as important as the magnitude
of the blood pressure. Measured blood pressure varies due to a
large number of factors such as measurement technique, accuracy
of equipment, and multiple patient factors such as anxiety. Even if
these factors are controlled, blood pressure is subject to biological
variation from beat to beat, minute to minute, and day to day.
Each blood pressure measurement is therefore analogous to a
single sample from a population of blood pressures. However, it is
a patient’s mean blood pressure over months and years that are
thought to determine his or her risk of cardiovascular disease. In
order to increase the precision of the estimated blood pressure,
clinical diagnosis is based on the average of 2 to 3 measurements
taken after resting for 5 minutes in a non-stimulating environment.
Despite such standardized procedures, BP remains highly variable
both within and between individuals. However, both this accepted
fact and the ease of describing such variability are not well
appreciated. Understanding to what extent BP is variable is very
important since the large variability of BP impacts diagnosis of
hypertension, clinical management of elevated BP and number of
drugs prescribed to achieve ‘‘BP control’’.
BP variability has been shown to increase with increasing blood
pressure and correlate with target-organ damage, independent of
absoluteBPvalues[1].However,theimportanceofBPvariabilityas
an independent risk factor remains controversial. In a study by
Pierdomenico S et al, after adjustment for other covariates in a Cox
multivariate analysis, the adverse prognostic impact of high BP
variability was no longer evident [2]. In fact the prognostic value of
BP variability has not been tested by proper longitudinal studies and
thefewavailable ones arelimited by smallstudy size, shortfollow up
or conclusions based on surrogate markers (progression of left
ventricular hypertrophy or arterial wall thickening) rather than on
the incidence of hard end points, such as cardiovascular events [3].
A better exploration of BP variability and of the influence of drugs
on BP variability may improve understanding of the mechanisms
involved in BP changes induced by drugs. We know that drugs
reduce cardiovascular risks, in different ways and to various extents,
by different mechanisms; however what is surprising is that we do
not clearly know the impact of these drugs on BP variability.
We have used the availability of a large amount of resting research
setting BP data from 33,611 patients, accumulated as part of two
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and describe some other characteristics of BP variability [4–7].
The objective of this study was to use standard deviation data
available from trials meeting the inclusion criteria of two
systematic reviews to answer the following three questions about
BP variability:
1. Does blood pressure entry criterion have an effect on baseline
BP variability?
2. Do thiazide diuretics have a significant effect on BP variability?
3. Does systolic blood pressure (SBP) vary to the same degree as
diastolic blood pressure (DBP)?
Methods
Standard Cochrane Hypertension Review group search strat-
egies was applied and the following databases were used - Medline,
EMBASE, and the Cochrane Clinical Trial Register from 1966–
2000 for systematic review 1 and up to 1998 for systematic review
2 to identify trials meeting the inclusion criteria. References of
previously published systematic reviews and bibliographic citations
of included studies were used to identify any additional trials [5,7].
Refer Figure 1 and 2 for quorum diagram.
Inclusion criteria
Both reviews included double blind randomized controlled trials
(RCTs) in adult patients with primary hypertension (defined as
SBP $140 mm Hg and/or DBP $90 mm Hg without an
identifiable cause). Review 1 –compared thiazide monotherapy
with placebo for 3–12 weeks duration and Review 2 – compared
thiazide as first-line therapy with placebo or untreated controls for
at least one year of therapy [4–7]. Although using individual
patient data would provide the most information about BP
variability, such analysis requires access to the raw data from trials,
which is seldom available in published trials. In this analysis we
used the standard deviation (SD) estimate of BP variability
reported in RCTs as the unit of analysis. In the included trials,
blood pressures were resting readings in a standardized research
setting: mean of 2 to 3 BP measurements (supine, sitting or
standing) taken after 5 minutes rest by trained certified technician
or nurse using standardized techniques with a mercury BP
manometer. The SBP reading was defined as the reading at the
first Korotkoff sound and DBP as the reading at the last Korotkoff
sound. Similar methods were used to measure blood pressure at
multiple visits during the trial period. Therefore our analysis
reflects total variability which includes both the within individual
variability and between individual variability of resting BP taken in
this standardized research setting. When the mean BP measure-
Figure 1. Quorum diagram for systematic review 1.
doi:10.1371/journal.pone.0005673.g001
Blood Pressure Variability
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each trial as our unit of measure and expressed our results as the
mean SD plus or minus standard error (SE). When the mean BP
measurement differed we used the coefficient of variation (CV),
the mean divided by the SD as the best way of comparing the
variability between the two measures.
Results
A total of 33 trials included in Review 1 (4,811 patients) and 16
trials included in Review 2 (29,351 patients) met the inclusion
criteria for the primary objectives of the two systematic reviews
[4,6]. 21/33 trials in Review 1 and 8/19 trials in Review 2
reported the baseline SBP and DBP variability. 21/33 trials in
Review 1 and 3/19 trials in review 2 reported the end of treatment
SBP and DBP variability.
In review 1 the resting baseline BP (mean of 3 readings) was
159/97 mm Hg and thiazide diuretic monotherapy as compared
to placebo reduced SBP by 26.8(27.7 to 25.9) mmHg and DBP
by 24.7(25.8 to 23.5) mm Hg over a mean duration of 8.8 weeks
[4]. In Review 2, the mean baseline BP was 163/95 mmHg and
first-line thiazide therapy plus further stepped care drugs as
necessary reduced systolic blood pressure by 214.7 (215.1 to
214.2) mm Hg and diastolic blood pressure by 26.5 (26.8 to
26.2) mm Hg after one year of treatment [6].
1. Does BP entry criterion have an effect on baseline BP
variability?
Trial entry criteria affected BP variability at baseline. When a
threshold SBP level is part of or the sole entry criterion, baseline
SBP variability as assessed by SD is significantly decreased from
14.0 to 9.3 mmHg. (see Table 1 for complete results). Likewise
when a threshold DBP level is part of or the sole the entry
criterion, baseline DBP variability as assessed by SD is significantly
decreased from 8.4 to 5.3 mmHg. (see Table 1).
Figure 2. Quorum diagram for systematic review 2.
doi:10.1371/journal.pone.0005673.g002
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variability?
Only review 1 data could be used to answer this question as in
review 2 other drugs besides thiazides were added [4]. As 31/33
trials in this review used DBP $90 mmHg as entry criteria and we
have demonstrated that this reduced the variability of DBP at
baseline (see above), we were mostly limited to SBP variability to
answer this question. In Table 2 this is demonstrated in two ways:
Firstly variability in SBP did not differ in the thiazide group
between baseline and end of treatment (paired t test). Secondly,
end of treatment SBP SD did not differ between the placebo and
thiazide group using an unpaired t test. We have further verified
this by comparing end of treatment diastolic SD using unpaired t
test in the placebo and thiazide treated group and they are also not
significantly different. (see Table 2). It must be remembered that
thiazides reduce the mean systolic and diastolic BP by 26.8/
24.7 mmHg respectively and therefore the mean blood pressures
are different at end of treatment. In that circumstance CV is a
better way to compare the BP variabilities as it corrects for the
difference in mean BP. In this instance the CV for systolic (9.9%)
and diastolic (8.2%) in the thiazide group are numerically higher
than the respective placebo groups, systolic (9.4%) and diastolic
(7.2%), but they are not statistically significantly different.
3. Does SBP vary to the same degree as the DBP?
For this analysis we used all the unconfounded measures of
systolic BP variability and diastolic BP variability from both
reviews. Systolic blood pressure SD as expected is greater than
diastolic blood pressure SD. Comparing the variability of the two
using CV showed the CV of SBP (9.2%) was significantly greater
than CV of DBP (8.3%). The results are shown in Table 3.
Discussion
We have demonstrated in this retrospective analysis that one of
the main factors that affect blood pressure variability in the
research setting is whether systolic or diastolic BP is used to decide
whether the patient is eligible for entry into a trial. When diastolic
blood pressure is used, it artificially reduces the variability of
diastolic blood pressure at baseline. Similarly, if systolic blood
pressure is used, it artificially reduces the variability of systolic
blood pressure at baseline. In this assessment the magnitude of this
effect in absolute terms is quite large (4.7 mmHg for SBP and
3.1 mmHg for DBP). Some reduction in variability for measures
used as entry criteria is not that surprising as the distribution of
baseline BP values is truncated at the threshold level of BP
required for entry into the trial. However, the large magnitude of
the effect suggests that it also reflects clustering of BP
measurements at the threshold entry criterion level, an effect that
is likely to reflect measurement bias. For example patients with
blood pressure slightly below the required entry level might have
their measurement increased by the researcher so that they meet
the entry level and can be recruited into the trial. The HOT trial,
one of the largest hypertension trials, is a good example of this
phenomenon [8]. In the HOT trial 18,970 patients were
randomized to three different TARGET blood pressures and a
Table 1. Does the blood pressure entry criterion have an effect on the baseline blood pressure variability?





Entry based on either SBP or
DBP criterion
Mean SD of SBP6SE mmHg 14.060.6 (n=41) 9.361.1* (n=5) 9.761.6* (n=10)
Mean SD of DBP6SE mmHg 5.360.3
{ (n=44) 8.460.7 (n=4) 4.660.6
{ (n=10)
SD=Standard Deviation; SE=Standard Error; SBP=Systolic Blood Pressure; DBP=Diastolic Blood Pressure; n=number of observations.
*p,0.01 unpaired t test of mean SD of SBP as compared to entry based on DBP criterion.
{p,0.01 unpaired t test of mean SD of DBP as compared to entry based on SBP criterion.
doi:10.1371/journal.pone.0005673.t001
Table 2. Do thiazides diuretics have a significant effect on
blood pressure variability?
Review 1 Thiazide group Placebo group
SD of SBP6SE mmHg
Baseline 14.960.99 (n=14)^ 14.160.75 (n=14)^
End of treatment^^ 14.360.71 (n=14) 14.060.82 (n=14)
CV of SBP6SE %
Baseline 9.560.57 (n=14)^ 9.060.39 (n=14)^
End of treatment^^ 9.960.42 (n=14) 9.460.53 (n=14)
SD of DBP6SE* mmHg
End of treatment^^ 7.660.37 (n=23) 6.960.39 (n=23)
CV of DBP6SE* %
End of treatment^^ 8.260.39 (n=23) 7.260.43 (n=23)
SD=Standard Deviation; SE=Standard Error; SBP=Systolic Blood Pressure;
DBP=Diastolic Blood Pressure; CV=Coefficient of Variation; n=number of
observations.
^Paired t test between baseline versus end of treatment is not significant for SD
of SBP as well as CV of SBP in both thiazide and placebo groups.
*Only end of treatment values for SD as well as CV of DBP were analyzed since
baseline values are confounded.
^^Unpaired t test at end of treatment between thiazide versus placebo groups
is not significant for SD as well as CV of both SBP and DBP.
doi:10.1371/journal.pone.0005673.t002
Table 3. Does systolic blood pressure vary to the same
degree as diastolic blood pressure?
Review (1+2)
Unconfounded baseline plus end of
treatment values in treatment and
control groups
SD of SBP6SE mmHg^ 14.060.4 (n=88)
SD of DBP6SE mmHg 7.7+0.3 (n=52)
CV of SBP6SE %^^ 9.260.2 (n=88)
CV of DBP6SE % 8.3+0.4 (n=52)
SD=Standard Deviation; SE=Standard Error; SBP=Systolic Blood Pressure;
DBP=Diastolic Blood Pressure; CV=Coefficient of Variation; n=number of
observations.
^p,0.0001 unpaired t test SD of SBP versus DBP.
^^p=0.04 unpaired t test CV of SBP versus DBP.
doi:10.1371/journal.pone.0005673.t003
Blood Pressure Variability
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trial the baseline systolic BP SD was 14.4, which is similar to our
estimate of the value 14.0 mmHg noted in Table 1 and 3.
However, in the HOT trial the diastolic blood pressure baseline
standard deviation was 3.4 mmHg. This is 4.3 mmHg lower than
our estimate of diastolic blood pressure SD, 7.7 mmHg (see
Table 3). This suggests that in the HOT trial there must have been
a large number of patients who had baseline diastolic blood
pressures of 100 mmHg thus partially explaining the large
reductions in BP seen in that trial in all 3 target groups.
Furthermore the end of treatment SD for both systolic,
11.6 mmHg, and diastolic blood pressure, 5.1 mmHg, are less
than the expected SD of about 14 mmHg for systolic and
8 mmHg for diastolic. This suggests that either that the drugs used
in that trial reduced BP variability or more likely that the process
of attempting to achieve a target blood pressure affected the blood
pressure measurements reported in a way that decreased their
variability. Knowledge of the expected variability of BP can be
used, as in this example, to detect data, of questionable validity.
When a marked difference in variability in BP from the expected
SD of blood pressures demonstrated here is seen in a trial, it could
be an indication that the data are fraudulent.
In contrast to the HOT trial the ALLHAT trial randomized
33,357 patients most of whom were selected because they were
previously treated [9]. There was therefore no threshold BP that
had to be achieved. In the ALLHAT trial the entry SBP SD was
16 mmHg and the DBP SD was 10 mmHg. This is higher than our
estimates of BP variability in the research setting and suggests that
BP variability in a cohort of treated patients is a little higher than in
an untreated population. Since this analysis shows that the
magnitude of the mean SBP/DBP reduction due to thiazides, 7/
5 mmHg in Review 1 and 15/7 mm Hg in Review 2, is the same as
or lower than mean BP variability of 14/10 mmHg, it is clear that
cliniciansaregoingto have a very difficult time assessingwhether an
antihypertensive drug is reducing BP and by what magnitude.
The most important question addressed in this analysis is
whether thiazides have an effect on BP variability. Thiazides have
been shown to lower blood pressure in many trials, but as far as we
are aware nobody has asked or tested whether they have an effect
on BP variability. If thiazides (or other antihypertensive treat-
ments) lower or raise BP variability, this could be clinically useful
or harmful, respectively. The data we have accumulated suggests
that thiazides do not have much effect on BP variability. However,
the lack of significance of BP variability between treated and
control groups could reflect the absence of any real difference, or
lack of power to show a difference. The small increase in both
systolic and diastolic CV in the end-of-treatment thiazide group
though not statistically significant, makes it probable that thiazides
do not decrease BP variability and possible that they could
increase BP variability. This should be tested with other databases
and preferably databases where individual patient data are
available. If there is an increase in variability associated with
thiazide treatment it would be important to determine whether it
was an increase in interpatient or intrapatient variability. It is
particularly the setting of an increase in intrapatient variability
that an antihypertensive therapy could increase risk to patients.
Systolic and diastolic BP measurements are dependent on each
other; however, there are physiologic settings where systolic BP rises
more than diastolic such as during exercise and as muscular arteries
lose their elasticity asa part of normalaging.In clinical trials, resting
bloodpressureismeasuredina standardizedway.Wearenot aware
of other settings where the variability of systolic and diastolic blood
pressure has been directly compared using the coefficient of
variation (the mean measurement divided by the SD). In this case
we have used all the unconfounded estimates of systolic BP and
compared them with all the unconfounded estimates of diastolic BP
to increase the chance of showing a difference. In the event the
systolic CV was statistically significantly greater than the diastolic
CV. This may reflect a true physiological difference. However, it is
more likely due to an artifact of the method of measurement. In this
case measurements were auscultatory using a mercury manometer.
Thismeansthat thesystolic BPis measuredfirstand the diastolicBP
is measured after a short delay. Because of this difference in timing
of the two measures patient factors could contribute to the
difference in variability e.g. Patients are more relaxed as the
pressure in the cuff decreases. Alternatively, it is easier to accurately
measure systolic blood pressure (appearance of first Korotkoff
sounds) than diastolic blood pressure (disappearance of Korotkoff
sounds). Thus the difficulty in detecting the disappearance could
lead to a greater likelihood of guessing, which would be expected to
artificially lower the variability of diastolic blood pressure. It will be
important to repeat this analysis with other data and in other
settings. For example a study of blood pressures measured with
automatic BP machines using an oscillometric technique may not
show a difference in variability of systolic and diastolic blood
pressure, thus providing evidence in favor of this being an artificial
difference caused by the technique of measurement. Whatever the
explanation for the statistically greater variability of systolic blood
pressure the magnitude of the increase in variability is small and
probably not clinically significant. We do not think that it is a reason
to suggest that diastolic blood pressure is a more reliable measure.
In conclusion, systematic reviews can often reveal much more
than the original objective of the work. Blood pressure variability
as estimated by SD is an important measure and researchers in the
area should be familiar with the average magnitude of that
variability, 14 mmHg for systolic and 8 mmHg for diastolic, and
the factors that can affect it. The impact of the large variability of
SBP/DBP needs to be taken in to account when hypertension is
diagnosed and when considering what represents ‘‘BP control’’
under treatment.
Most importantly, we need to learn more about the relationship
between BP variability and cardiovascular outcomes plus the effect
of specific drug treatments on blood pressure variability. We
believe that BP variability is a neglected but important measure
that deserves more attention.
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